| Name | Title | Contact Details |
|---|
Gympass is a complete corporate wellbeing platform that ignites every journey to feel good. We`re reinventing wellbeing, making it engaging and accessible. Worldwide companies rely on Gympass` unmatched variety, convenience, and flexibility to support their employees` health and happiness. We partner with best in class wellbeing providers in multiple markets across North America, Latin America, and Europe. With over 50,000 fitness partners, 1,300 on demand classes, 2,000 hours of meditation, 1,000 healthy recipes, weekly 1:1 therapy sessions, and hundreds of personal trainers, Gympass supports every wellbeing journey.
VisuWell is the leader in patient-centered, innovative, and affordable virtual care solutions. The VisuWell platform is an easy-to-use, enterprise-ready, browser-deployed technology increasing healthcare access for health systems, ambulatory care organizations, and payors. VisuWell offers patients and providers a comprehensive telehealth experience for consults, triage, telemedicine visits, and remote patient monitoring over a wide variety of use cases and environments. VisuWell enables care organizations to utilize their own provider networks to offer easy-to-access, high-quality care. The VisuWell platform creates a tailored virtual experience accommodating 35+ use cases serving thousands of locations and helping millions of people to see healthcare differently.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
LifeMed Media, Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Chinese Community Health Plan is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.